Obesity is associated with impaired responsiveness to once-daily low-dose aspirin and in vivo platelet activation.
Adult
Aspirin
/ administration & dosage
Biological Availability
Biomarkers
/ blood
Body Mass Index
Body Weight
Case-Control Studies
Computer Simulation
Drug Administration Schedule
Female
Humans
Male
Middle Aged
Models, Biological
Obesity
/ blood
Pilot Projects
Platelet Activation
/ drug effects
Proof of Concept Study
Thromboxane A2
/ biosynthesis
Thromboxane B2
/ blood
aspirin
body mass index
obesity
platelets
thromboxane A2
Journal
Journal of thrombosis and haemostasis : JTH
ISSN: 1538-7836
Titre abrégé: J Thromb Haemost
Pays: England
ID NLM: 101170508
Informations de publication
Date de publication:
06 2019
06 2019
Historique:
received:
20
02
2019
accepted:
28
03
2019
pubmed:
2
4
2019
medline:
1
7
2020
entrez:
2
4
2019
Statut:
ppublish
Résumé
The prevalence and degree of obesity is rising worldwide, increases cardiovascular risk, modifies body composition and organ function, and potentially affects the pharmacokinetics and/or pharmacodynamics of drugs. To investigate the pharmacodynamics of once-daily low-dose aspirin in healthy obese subjects, and to assess whether body weight (BW) and body mass index (BMI) affect the pharmacology of aspirin. Otherwise healthy, obese (BMI > 30 kg/m In 16 obese subjects (aged 47 ± 11 years; BMI of 39.4 ± 5.1 kg/m Obesity is associated with impaired aspirin responsiveness, largely because of body size. Impaired inhibition of platelet activation by conventional low-dose aspirin may affect antithrombotic efficacy.
Sections du résumé
BACKGROUND
The prevalence and degree of obesity is rising worldwide, increases cardiovascular risk, modifies body composition and organ function, and potentially affects the pharmacokinetics and/or pharmacodynamics of drugs.
OBJECTIVES
To investigate the pharmacodynamics of once-daily low-dose aspirin in healthy obese subjects, and to assess whether body weight (BW) and body mass index (BMI) affect the pharmacology of aspirin.
PATIENTS/METHODS
Otherwise healthy, obese (BMI > 30 kg/m
RESULTS
In 16 obese subjects (aged 47 ± 11 years; BMI of 39.4 ± 5.1 kg/m
CONCLUSIONS
Obesity is associated with impaired aspirin responsiveness, largely because of body size. Impaired inhibition of platelet activation by conventional low-dose aspirin may affect antithrombotic efficacy.
Identifiants
pubmed: 30933424
doi: 10.1111/jth.14445
pii: S1538-7836(22)04444-0
doi:
Substances chimiques
Biomarkers
0
Thromboxane B2
54397-85-2
Thromboxane A2
57576-52-0
Aspirin
R16CO5Y76E
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
885-895Informations de copyright
© 2019 International Society on Thrombosis and Haemostasis.